Evidence map›Paper›PMID 39353703›Full record

SynthesisOpen heart2024

Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and meta-analysis.

Natalija Odanović, Alexandra N Schwann, Zhiyuan Zhang, Sohum S Kapadia, Steffne J Kunnirickal, Helen Parise, Daniela Tirziu, Ivan Ilic, Alexandra J Lansky, Cody G Pietras and 1 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Open heart, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Review
  3. Quantitative imaging in medicine and surgery · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Invasive Endotyping of Angina Pectoris with Nonobstructive Coronary Arteries.The International journal of angiology : official publication of the International College of Angiology, Inc · 2025
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Natalija OdanovićInstitute for Cardiovascular Diseases "Dedinje", Belgrade, Serbia.ORCID 0000-0003-0343-6195
Alexandra N SchwannDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Zhiyuan ZhangDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Sohum S KapadiaDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Steffne J KunnirickalDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Helen PariseDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Daniela TirziuDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Ivan IlicInstitute for Cardiovascular Diseases "Dedinje", Belgrade, Serbia.
Alexandra J LanskyYale Cardiovascular Research Group, Yale Medical School, New Haven, Connecticut, USA.
Cody G PietrasDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Samit M ShahDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA samit.shah@yale.edu.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

backgroundThe prognosis of myocardial ischaemia with no obstructive coronary artery disease (INOCA) and its underlying vasomotor disorders, vasospastic angina (VSA) and microvascular angina (MVA), is not well defined. The aim of this study was to perform a systematic review and meta-analysis of studies evaluating the long-term prognosis of patients with INOCA.

methodsWe included studies evaluating the prognosis of patients with INOCA published between January 1984 and August 2023 in Medline, Embase, Web of Science and Cochrane databases. Studies were selected if they included patients who fulfilled the Coronary Vasomotor Disorders International Study Group (COVADIS) criteria for either possible or definitive VSA or MVA. The primary outcomes were composite of all-cause death and myocardial infarction (MI), and major adverse cardiovascular event (MACE) at annual intervals up to 5-year follow-up. The incidence of primary outcomes for INOCA, each INOCA endotype and by method used to determine the diagnosis was calculated using the random effects model.

resultsFifty-four studies (17 302 patients) meeting the eligibility criteria were selected. The rate of all-cause death and MI with VSA was 0.7 (95% CI 0.4 to 1.0)/100 patient-years and with MVA was 1.1 (95% CI 0.7 to 1.5)/100 patient-years (p>0.05). The rate of MACE with VSA was 1.1 (95% CI 0.5 to 1.9)/100 patient-years and with MVA was 2.5 (95% CI 1.6 to 3.6)/100 patient-years (p=0.025). Patients with reduced coronary flow reserve (CFR) had higher all-cause death and MI rates than patients whose diagnosis of MVA was established based on an abnormal exercise or imaging stress test (4.7 (95% CI 2.0 to 8.4) vs 0.5 (95% CI 0.1 to 1.1) vs 1.1 (95% CI 0.5 to 2.0)/100 patient-years, p=0.001).

conclusionsOverall, patients with INOCA have a low rate of MACEs, but patients with MVA, especially those with reduced CFR, have a significantly higher rate of MACE than other subgroups, although there is high heterogeneity among the included studies. PROSPERO REGISTRATION NUMBER: CRD42021275070.

Indexed as

Myocardial IschemiaCause of DeathCoronary Artery DiseaseCoronary VasospasmGlobal HealthHumansMicrovascular AnginaPrognosisRisk AssessmentRisk FactorsTime FactorsAngina PectorisMeta-AnalysisMicrovascular Angina

Identifiers

PMID39353703
PMCPMC11448144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.